Royalty Pharma (STU:RPD) Other Operating Expense : €459 Mil (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Royalty Pharma Other Operating Expense?

Royalty Pharma's Other Operating Expense for the three months ended in Sep. 2024 was €-205 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 was €459 Mil.

Royalty Pharma's quarterly Other Operating Expense declined from Mar. 2024 (€537 Mil) to Jun. 2024 (€197 Mil) and declined from Jun. 2024 (€197 Mil) to Sep. 2024 (€-205 Mil).

Royalty Pharma's annual Other Operating Expense increased from Dec. 2021 (€421 Mil) to Dec. 2022 (€859 Mil) but then declined from Dec. 2022 (€859 Mil) to Dec. 2023 (€514 Mil).

Royalty Pharma Other Operating Expense Historical Data

The historical data trend for Royalty Pharma's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma Other Operating Expense Chart

Royalty Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Operating Expense

Get a 7-Day Free Trial

-895.86

208.70

421.12

858.96

514.12

Royalty Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Operating Expense	Get a 7-Day Free Trial															259.68	-70.16	536.91	197.35	-205.07

Royalty Pharma Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €459 Mil.

Royalty Pharma Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Royalty Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (STU:RPD) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

RPRX:USA RPRX:Mexico RPD:Germany

Address

110 East 59th Street, New York, NY, USA, 10022

Website

https://www.royaltypharma.com

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.